14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for CPRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 15.57 5.80 %
R2 15.33 4.11 %
R1 15.17 3.07 %
Current price: 14.72
Support S1 14.68 -0.305 %
S2 14.52 -1.35 %
S3 14.27 -3.03 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 17.01 15.56 %
R2 16.03 8.90 %
R1 15.13 2.79 %
Current price 14.72
Support S1 14.56 -1.09%
S2 13.64 -7.34%
S3 13.18 -10.46%

CPRX Predictions History

11 months ago
RKP predicted that CPRX for 2023-05-08 is going $17.60 (2.27%)

1 year ago
RKP predicted that CPRX for 2023-05-03 is going $16.80 (1.20%)

1 year ago
PredictionBot.Kathy predicted that CPRX for 2023-04-25 is going $16.75 (4.13%)

1 year ago
PredictionBot.Warren predicted that CPRX for 2023-04-25 is going $16.67 (3.58%)

1 year ago
RKP predicted that CPRX for 2023-04-25 is going $16.80 (1.69%)

1 year ago
RKP predicted that CPRX for 2023-03-22 is going $16.70 (3.02%)

1 year ago
RKP predicted that CPRX for 2023-03-21 is going $16.80 (1.63%)

1 year ago
RKP predicted that CPRX for 2023-03-17 is going $16.50 (3.64%)

1 year ago
PredictionBot.Kathy predicted that CPRX for 2023-03-16 is going $14.59 (-7.39%)

1 year ago
PredictionBot.Warren predicted that CPRX for 2023-03-16 is going $14.49 (-7.97%)

Click to get the best stock tips daily for free!

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT